Cancer Archive — Page 33 of 67

April 23, 2020

Polygenic scores identify those at high cancer risk

A team of Vanderbilt researchers constructed polygenic risk scores (PRS) based on genomic variants associated with eight common cancers and concluded they could potentially be used for personalized risk assessments.

By Tom Wilemon
April 23, 2020

Study explores melanoma drug’s effectiveness

A study by Vanderbilt research-ers supports the clinical development of a new second-line treatment for metastatic melanoma.

By Tom Wilemon
The extracellular RNA in colorectal cancer team includes, from left, Jeffrey Franklin, PhD, Yu Shyr, PhD, Qi Liu, PhD, Alissa Weaver, MD, PhD, James Higginbotham, PhD, and James Patton, PhD. Not pictured: Robert Coffey, MD, Kasey Vickers, PhD, and John Karijolich, PhD. (photo taken before social distancing)
April 9, 2020

Research team awarded $9 million to study extracellular RNA in colorectal cancer

The NCI program project grant is supporting multiple projects that aim to define fundamental biological principles about extracellular RNA signaling and the development and aggressiveness of colorectal cancer, the second leading cause of cancer death in the United States.

By Leigh MacMillan
April 9, 2020

Study tracks genomics of lung tumor behavior

A study by Vanderbilt researchers has identified genomic alterations in early stage adenocarcinomas of the lung that may indicate whether the lesions develop into aggressive tumors.

By Tom Wilemon
April 2, 2020

Researcher works on protocols to implement screening for gastric cancer

A Vanderbilt gastroenterologist is helping lead an effort to establish screening guidelines for gastric cancer in the United States, where the number of people at risk for the cancer is increasing as the nation’s population becomes more diverse.

By Tom Wilemon
March 23, 2020

Study reveals an inherited origin of prostate cancer in families

Vanderbilt researchers have identified haplotypes, ancestral fragments of DNA, that are associated with hereditary prostate cancer (HPC) in a first-of-its-kind genomic study made possible by the study of prostate cancer patients with family histories of the disease.

By Tom Wilemon